VeraCept
Phase 3Protein / enzyme
VeraCept is one of 50 small molecule programs targeting Efficacy. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
139 competitors in Efficacy
#DrugCompanyPhaseTrials
1Rayos
RRoxane Laboratories
Phase 3
Paraplatin
AAvyxa
Phase 3
Lesinurad
EEsperion Therapeutics, Inc.
Phase 3
Insulin 320
Novo NordiskPhase 3
Sepofarsen
PProQR Therapeutics
Phase 3
Endothelin Receptor Antagonist
RRadboud University Medical Center
Phase 3
VeraCept
SSebela Women's Health Inc.
Phase 3
Cetaphil
GGalderma R&D
Phase 3
Aralen
SanofiPreclinical
Primaquine
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VeraCept. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company
- SSebela Women's Health Inc.